Nestle China JV Backs Nutritional And Rx Botanical Development
This article was originally published in The Tan Sheet
Executive Summary
Nestle Health Science and Chi-Med’s joint venture Nutrition Science Partners creates an opportunity to develop and commercialize scientifically validated botanical nutritionals and drugs, based in part on Chi-Med’s traditional Chinese medicine library of 1,200 plants and 50,000 extracts.
You may also be interested in...
In Brief
Perrigo divests personal hygiene assets; P&G sues whitening strip private labeler; Purimune contamination prompts Baby Move recall; FDA sounds alarm on Oto-Ease recall; more news In Brief.
Nestle Health Science Plans Continuum Of Care
Nestle's announcement that its Health Science division is buying gastrointestinal drug developer and diagnostics firm Prometheus Laboratories takes the food company in a new direction, raising questions about Nestle's possible pharmaceutical play.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”